Fourchette de valorisation composite · prudent $22–$24 / raisonnable $29–$39 / optimiste $53–$58. À $29.91, Dans la fourchette de valeur intrinsèque raisonnable.
Early LB2501 in vivo CAR-T data showed responses in all six high-dose non-Hodgkin lymphoma patients, driving a sharp share rally.
Possible impact:May affect expectations for Legend's in vivo CAR-T platform, pipeline value, and potential strategic premium.
WSJ said J&J faces pressure in the in vivo CAR-T race, with Legend drawing attention due to Carvykti and its platform.
Possible impact:May affect investor expectations for a J&J acquisition or deeper collaboration, increasing event-driven attention.
J&J exited some biotech holdings but retained 814,586 Legend Biotech shares, reinforcing the backdrop for takeover speculation.
Possible impact:May affect market views on the strategic relationship's durability and possible transaction odds.
Automatically summarized from public sources; for context only, not investment advice.
Données EODHD, présentées dans la devise de reporting ; à titre indicatif uniquement, ne constitue pas un conseil en investissement.
Legend Biotech Corporation, through its subsidiaries, operates as a biopharmaceutical company that discovers, develops, manufactures, and commercializes novel cell therapies for oncology and other indications in the United States, China, and Europe. Its lead product candidate is ciltacabtagene autoleucel, or cilta-cel, which is a chimeric antigen receptor (CAR-T) therapy for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, small cell lung cancer, and non-small cell lung cancer. In addition, it develops allogeneic gamma delta CAR-T and allogeneic CAR-NK product candidates targeting B-cell maturation antigen (BCMA) for MM, which are in investigator-initiated Phase 1 clinical trials in China. The company has a collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of cilta-cel, as well as a license agreement with Novartis Pharma AG for the development, manufacture, and commercialization of CAR-T cell therapies targeting delta-like ligand protein 3. Legend Biotech Corporation was founded in 2014 and is headquartered in Somerset, New Jersey.
Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.
Bientôt disponibleCette section est en cours de complétion ; revenez bientôt.
Pas encore d'analyse sur cette valeur dans votre langue.
